Thoroughbred Financial Services LLC trimmed its position in Johnson & Johnson (NYSE:JNJ – Free Report) by 19.7% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 38,537 shares of the company’s stock after selling 9,468 shares during the quarter. Thoroughbred Financial Services LLC’s holdings in Johnson & Johnson were worth $6,096,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors have also recently bought and sold shares of JNJ. Christopher J. Hasenberg Inc bought a new position in Johnson & Johnson in the 1st quarter valued at about $31,000. Keener Financial Planning LLC acquired a new position in Johnson & Johnson in the fourth quarter worth approximately $40,000. WFA Asset Management Corp grew its holdings in Johnson & Johnson by 61.4% during the fourth quarter. WFA Asset Management Corp now owns 255 shares of the company’s stock valued at $40,000 after purchasing an additional 97 shares during the last quarter. Vermillion & White Wealth Management Group LLC acquired a new position in Johnson & Johnson during the fourth quarter valued at approximately $44,000. Finally, Disciplined Equity Management Inc. bought a new stake in shares of Johnson & Johnson in the fourth quarter valued at approximately $45,000. 69.55% of the stock is owned by institutional investors and hedge funds.
Johnson & Johnson Price Performance
NYSE:JNJ traded up $0.90 on Tuesday, reaching $150.14. 1,700,777 shares of the company’s stock traded hands, compared to its average volume of 7,230,960. Johnson & Johnson has a 12 month low of $143.13 and a 12 month high of $175.97. The company has a quick ratio of 0.94, a current ratio of 1.17 and a debt-to-equity ratio of 0.36. The stock has a 50-day simple moving average of $147.95 and a 200-day simple moving average of $153.41. The firm has a market cap of $361.34 billion, a PE ratio of 9.37, a P/E/G ratio of 2.52 and a beta of 0.52.
Analyst Upgrades and Downgrades
JNJ has been the subject of a number of analyst reports. The Goldman Sachs Group started coverage on Johnson & Johnson in a report on Thursday, May 30th. They set a “neutral” rating and a $160.00 price objective for the company. Morgan Stanley cut their target price on Johnson & Johnson from $168.00 to $167.00 and set an “equal weight” rating on the stock in a research note on Wednesday, April 17th. HSBC raised Johnson & Johnson from a “hold” rating to a “buy” rating and boosted their target price for the stock from $169.00 to $170.00 in a report on Thursday, April 18th. Royal Bank of Canada reiterated an “outperform” rating and set a $175.00 target price on shares of Johnson & Johnson in a research report on Monday, June 17th. Finally, Bank of America cut their target price on Johnson & Johnson from $180.00 to $170.00 and set a “neutral” rating for the company in a research report on Wednesday, April 17th. Eight equities research analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $174.07.
View Our Latest Report on Johnson & Johnson
Johnson & Johnson Company Profile
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.
Further Reading
- Five stocks we like better than Johnson & Johnson
- Financial Services Stocks Investing
- Could the Economy be Bottoming? Major Bank’s Earnings Say Yes
- 3 Home Improvement Stocks that Can Upgrade Your Portfolio
- Seize This Prime Stock Opportunity on Amazon Prime Days
- The How and Why of Investing in Gold Stocks
- Crypto Stocks Back on the Radar: Top Picks to Watch
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Free Report).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.